Initiator Pharma successfully completes the preclinical development of its Erectile Dysfunction drug candidate IPED2015 ahead of time
PRESS RELEASE January 22, 2018 Initiator Pharma, a Biotech Company developing a novel treatment of Erectile Dysfunction (ED), has successfully completed the preclinical development of its drug candidate IPED2015. The studies were concluded ahead of the previously announced schedule and included experimental work with most of the recent positive data from the cardiovascular telemetry study, the respiratory study and a clean genotoxicity profile.“With the positive results from the final studies in genotoxicology and safety pharmacology of the preclinical development of IPED2015 we have